Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-masked, Controlled, Safety and Tolerability Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)

NCT06812325 is registered in ClinicalTrials.gov with Viridian Therapeutics, Inc. as lead sponsor.

NCT NCT06812325
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06812325 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-masked, Controlled, Safety and Tolerability Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)
Lead sponsor
Viridian Therapeutics, Inc.
Phase
Phase 3
Overall status
Active, not recruiting
Start date
February 3, 2025
Completion date
October 31, 2026
Enrollment
320 (actual)
Sites
64

Conditions

As the registry lists them; a condition with its own page is linked.

thyroid eye disease (ted)